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ABSTRACT Genomic instability is associated with increased oxidative stress in patients with human immunodeficiency virus
(HIV). The aim of this study was to determine the effect of intake of methanolic and aqueous extracts of Rosmarinus officinalis on
genomic instability in HIV patients. We studied 67 HIV patients under pharmacological treatment with ATRIPLA who were
divided into three groups: group 1, patients under ATRIPLA antiretroviral therapy; group 2, patients with ATRIPLA and rosemary
aqueous extract (4 g/L per day); and group 3, patients with ATRIPLA and rosemary methanolic extract (400 mg/day). The genomic
instability was evaluated through the buccal micronucleus cytome assay. Oral epithelial cells were taken at the beginning and 1 and
4 months later. The groups that received the pharmacological therapy with ATRIPLA and the complementary therapy with
R. officinalis extracts showed a decrease in the number of cells with micronuclei and nuclear abnormalities compared with the group
that only received ATRIPLA. The complementary therapy with R. officinalis decreased the genomic instability in HIV patients.
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INTRODUCTION
The human immunodeficiency virus (HIV) representsa very complex public health problem. The antiretrovirals
have effect on reducing morbidity and mortality, prolonging
lives and improving the quality of life of many people living
with HIV infection.1,2
However, it has been shown that there is an increase in
reactive oxygen species (ROS) following the administration
of antiretroviral therapy, even on a larger scale when com-
pared with HIV individuals without treatment. These obser-
vations suggest that HIV infection alone or in combination
with antiretrovirals induce oxidative stress, favoring their
progression of pathogenesis by HIV.3,4
Current research focuses on ROS since they play a central
role in the deterioration of systems and, consequently, they
generate the progression of pathologies such as HIV.5
Increase of ROS is associated with the oxidation of nu-
cleosides, which could cause DNA strand breaks,6 produc-
ing teratogenic or carcinogenic consequences.7 The use of
plants with antioxidant property in HIV patients could re-
store the cellular balance.
Plants have efficient complex enzymatic antioxidant defense
systems (such as superoxide dismutase, catalase, glutathione
peroxidase, and glutathione reductase) and nonenzymatic an-
tioxidants (low-molecular-weight antioxidants, ascorbic acid,
glutathione, proline, carotenoids, phenolic acids, flavonoids,
and high-molecular-weight secondary metabolites such as tan-
nins) to avoid the toxic effects of free radicals.8,9
Rosmarinus officinalis is a medicinal plant distributed
throughout the world and is responsible for pharmacological
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activities, such as anti-inflammatory, antioxidant, antimi-
crobial, antihyperglycemic, antiproliferative, antitumor, and
protective, inhibitory, and attenuating activities.10
The best known phytocompounds of R. officinalis include
caffeic acid, carnosic acid, chlorogenic acid, monomeric acid,
oleanolic acid, rosmarinic acid, ursolic acid, alpha-pinene,
camphor, carnosol, eucalyptol, rosmadial, rosmanol, rosma-
quinones A and B, secohinokio, and eugenol and luteolin
derivatives.10
The main constituents with antioxidant properties are car-
nosic acid and carnosol (responsible for 90% of the proper-
ties). Both are inhibitors of lipid peroxidation in liposomal and
microsomal systems; they are good scavengers of peroxyl
radicals, which reduce cytochrome c and scavenge hydroxyl
radicals. Specifically, carnosic acid scavenges H2O2 but could
also act as a substrate for the peroxidase system.11
Caffeic acid of rosemary activates the extracellular-signal-
regulated kinase signaling pathway by a relatively low level
of ROS, which block H2O2-induced DNA double-strand
breaks and improve the viability of human liver cells.12
Rosmarinic acid increases the protein expression of Bax,
and cleaved form of PARP-1 proapoptotic protein Bax and
antiapoptotic protein Bcl-2 family bound to the mitochondrial
membrane affect the intrinsic mitochondrial pathway of apo-
ptosis by regulating efflux of cytochrome c from mitochondria
to the cytoplasm, and subsequent activation of caspases such
as caspase-3, -6, and -7 that are cysteine-aspartic proteases
plays important roles in apoptosis. (PARP-1 is a poly-[ADP-
ribosylating] enzyme necessary for DNA repair process.)13,14
The genomic instability can be evaluated through comet
test (single-cell gel electrophoresis assay), FISH (fluores-
cence in situ hybridization), CGH (comparative genomic
hybridization), TUNEL (terminal deoxynucleotidyl transfer-
ase [TdT] dUTP nick-end labeling) assay, micronucleus
(MN) assay, and nuclear abnormalities (NAs), among oth-
ers.15 The buccal micronucleus cytome (BMCyT) assay is a
minimally invasive cytological and interphase cytogenetic
technique for measuring DNA damage and cell death bio-
markers in the oral epithelium, the size, density, and distri-
bution of chromatin experiment change, which lead to DNA
damage.16
The present work aimed to determine the effect of in-
gestion of methanolic and aqueous extracts of R. officinalis
on genomic instability in HIV patients through the BMCyT
assay.
MATERIALS AND METHODS
Study design and participants
We studied 67 HIV patients of the Centro Ambulatorio para
la Prevención y Atención en SIDA e Infecciones de Trans-
misión Sexual (CAPACIT), Zacatecas, Zacatecas, México.
The inclusion criteria included patients of legal age, in-
distinct sex, without complications due to the disease, and
those who are only under pharmacological treatment with
ATRIPLA (efavirenz 600 mg, emtricitabine 200 mg, and
tenofovir disoproxil fumarate 300 mg).
The participants gave their informed written consent. The
work was carried out in accordance with the Declaration of
Helsinki, and it was approved by the Local Health Research
Committee 3301 of the ‘‘Hospital General Zona/MF 1 Za-
catecas’’ (Registration No. R-2019-3301-043) and also
meets the registry before COMBIOETICA Committee
(32 CEI 001 2017082) and COFEPRIS (17 CI 32 056 012)
The patients with HIV were divided into three groups:
group 1, the follow-up group (n = 22), patients who only
continued their pharmacological therapy with ATRIPLA.
Group 2, patients who in addition to their pharmacologi-
cal therapy with ATRIPLA had complementary therapy
with rosemary aqueous extract at a dose of 4 g/L per day
for 4 months (n = 22). Group 3, patients who in addition to
their pharmacological therapy with ATRIPLA had com-
plementary therapy with rosemary methanolic extract at a
dose of 400 mg/day for 4 months (n = 23), and a control
group consisting apparently healthy people was added
(n = 22).
The dosage of the rosemary aqueous and methanolic ex-
tracts was based on previous studies reported by Lazalde-
Ramos et al.17,18
Each patient underwent a clinical history, with emphasis
on the development of HIV.
The samples of the oral mucosa were taken before starting
the complementary therapy and every 30 days for 4 months
Plant material and preparation of the extract
The rosemary leaves used were acquired from Medicinal
Plants of America, S.A. of C.V. Mexico, D.F. lot number
100210.
Rosemary aqueous extract: Infusion extraction method. A
box containing 30 sachets of rosemary leaves (4 g each)
were provided to each patient who belonged to the com-
plementary therapy group with rosemary aqueous extract.
The rosemary leaves used were packaged in accordance
with the Official Mexican Standard NOM-072-SSA1-2012
in the ethnopharmacology laboratory of the Autonomous
University of Zacatecas. The preparation form was based on
a previously published study by Lazalde-Ramos et al.,17 in a
liter of boiling water, add a bag of rosemary leaves and
allow it to boil for 3 min and then pass through a sieve to
remove the leaves. Patients were instructed to consume it as
drinking water during the day.
Preparation of rosemary methanolic extract. The me-
thanolic extract was extracted as previously described by
Gutiérrez et al.19 The dry leaves were pulverized into fine
powder, macerated in methanol for 24 h, the proportion was
10 g of the rosemary leaf powder in 100 mL of methanol,
and subjected to a reflux system for 2 h at 70C. The chlo-
rophyll was removed with activated carbon. Subsequently, it
was distilled by means of a rotary evaporator system and
precipitated with tridistilled water at -4C, and the precip-
itate was dried and encapsulated according to NOM-072-
SSA1-2012. Yield extraction was 14%.




























































From each participant, buccal mucosa samples were col-
lected using a precoded slide. Subjects were asked to rinse their
mouths with water, before taking the samples. Cells from the
buccal mucosa were collected by scraping both cheeks with a
slide with a ground edge. The obtained cells were spread di-
rectly on separate precoded slides in duplicate.20
The slides were air-dried and fixed with 80% methanol
for 48 h and then stained with acridine orange (CAS No.
10127023; Sigma–Aldrich, St. Louis, MI).
Precoded slides were examined by one reader according
to the criteria described by Thomas et al.21 The cells were
counted blindly as NAs including MN, binucleated cells
(BN), cells with nuclear buds (NBs), karyolysis (KL), kar-
yorrhexis (KR), abnormally condensed chromatin (CC), and
pyknosis (PYK). The number of cells with NAs was evalu-
ated among 2000 cells using an Olympus CX31 microscope
equipped with epifluorescence and oil immersion objective
(100 · ; Olympus, Tokyo, Japan). The results are presented
as the number of cells with NAs per 2000 cells. NAs were
evaluated by assessing the staining intensity, texture, and
focal plane of the nucleus. Normal cells were identified as
follows: intact and relative homogeneous cytoplasm, little or
no contact with adjacent cells, and an intact homogeneous
nucleus with a smooth and distinct nuclear perimeter.21,22
Statistical analysis
The results are presented as mean – standard deviation
(SD). The increase or decrease in percentage was calculated
by dividing the final value by the initial one, and the value
obtained was multiplied by 100 and the remainder was 100%.
Differences in MN and NA values were evaluated using
the Wilcoxon signed-rank test for intragroup comparison,
and the intergroup analysis was performed using the Mann–
Whitney U test. All tests were performed using the Statis-
tical Program for the Social Sciences (SPSS v.20) for
Windows medical pack (SPSS, Chicago, IL). A P-value of
<.05 was considered statistically significant.
RESULTS
The average age of the HIV patients was 40.5 – 10.5
years, with a progression of the disease of 7.08 – 5.27 years;
all patients acquired the disease sexually.
The results obtained from the BMCyT assay in the study
groups, at the different sampling times, are shown in Table 1.
The patients who received only the pharmacological
therapy with ATRIPLA showed an increase at 120 days in
the number of cells with MN (50.27%), BN (51.36%), and
KR (12.71%), with statistically significant increase in the
number of cells with BN.
The groups that received the pharmacological therapy
with ATRIPLA and the complementary therapy with rose-
mary showed a decrease in the number of cells with MN and
NAs, the decrease being greater in the patients who received
the complementary therapy with rosemary methanolic ex-
tract (Table 1).
Figure 1 shows the results obtained from the difference
between the baseline value and that obtained after 4 months
of treatment in the study groups.














Control group Basal 0.56 – 0.58 2.43 – 1.44 0.60 – 0.65 2.91 – 2.29 0.73 – 1.35 1.17 – 1.43 0.34 – 0.57
HIV patients with
ATRIPLA
Basal 0.81 – 1.0 48.50 – 18.56 16.72 – 12.59 146.18 – 55.29 30.63 – 28.28 52.90 – 32.73 10.04 – 13.37
120 days 1.22 – 1.45 48.50 – 22.21 25.31 – 25.75 143.31 – 60.00 29.72 – 28.12 59.63 – 34.10 8.40 – 10.10
P NS NS .014b NS NS NS NS
Increase or
decrease – (%)






Basal 0.82 – 0.98 16.65 – 4.90 5.30 – 3.64 77.00 – 31.61 24.13 – 20.22 21.78 – 12.53 6.43 – 4.46
30 days 0.17 – 0.38 12.78 – 7.84 3.56 – 3.14 56.34 – 28.92 16.13 – 8.76 11.56 – 8.15 6.47 – 3.85
120 days 0.17 – 0.38 9.43 – 5.02 1.60 – 2.29 35.30 – 11.88 16.56 – 11.83 10.39 – 6.59 4.86 – 4.93











Basal 1.00 – 1.77 27.18 – 17.60 11.68 – 9.33 100.13 – 42.23 15.45 – 22.42 36.27 – 32.90 10.50 – 16.32
30 days 1.04 – 1.25 21.90 – 19.89 9.90 – 7.32 77.81 – 42.80 6.77 – 9.99 26.00 – 21.98 4.90 – 11.40
120 days 0.63 – 1.36 18.72 – 24.56 5.18 – 5.08 48.40 – 41.98 9.09 – 13.17 19.54 – 17.38 4.59 – 8.33
P NS .005b .002b, .007c .024a, .001b,c .033a .003b .011a, .025b
Increase or
decrease – (%)
-36.4 -31.10 -55.64 -51.65 -41.18 -46.11 -56.28
Data are expressed as mean – SD. Results are presented as the number of cells with MN and NAs per 2000 cells. Statistical significance was considered with
P < .05. Differences in MN and NA values were evaluated using the Wilcoxon signed-rank test for intragroup comparison (basal value vs. 30 daysa, basal values vs.
120 daysb, and 30 days vs.120 daysc). The increase or decrease was determined to the 120 days in relation to basal time.
MN, micronucleus; NAs, nuclear abnormalities; NS, not significant.



























































FIG. 1. Intergroup comparison between the differences obtained at 4 months and the baseline value of the number of cells with MN and NAs. The
comparisons were performed using the Mann–Whitney U test; it was considered statistically significant when P < 0.05. BN, binucleated cells; CC,




























































The patients who received only the pharmacological
therapy with ATRIPLA showed an increase in the number of
cells with MN, BN, KR, and NBs; however, the patients who
received the pharmacological therapy with ATRIPLA and
the complementary therapy with rosemary showed a de-
crease in the number of these cells.
The number of cells with KL, CC, and PYK decreased in
all the groups. The number of cells with CC decreased sta-
tistically in the patients who received the pharmacological
therapy with ATRIPLA and the complementary therapy with
rosemary. In relation to the number of cells with KL and
PYK, only the group of patients who received the pharma-
cological therapy with ATRIPLA and the complementary
therapy with rosemary aqueous extract showed a statistically
significant decrease.
In the intergroup comparison, there was a statistically
significant difference in the number of cells with MN,
BN, CC, and KR between the patients who received the
pharmacological therapy with ATRIPLA and those who
received the pharmacological therapy with ATRIPLA and
the complementary therapy with rosemary methanolic
extract; this number being lower in the group of patients
who received the complementary therapy with rosemary
methanolic extract.
Similarly, in the group of patients who received the com-
plementary therapy with rosemary aqueous extract, there was
a statistically significant decrease in the number of cells with
BN, CC, and KR when compared with the group of patients
who received only the pharmacological therapy with ATRI-
PLA (Fig. 1)
DISCUSSION
HIV remains one of the most serious public health
problems in the world, especially in developing countries.
The antiretroviral therapy in HIV individuals increases the
time and quality of life and decreases the incidence of op-
portunistic diseases associated with the AIDS phase. Com-
bined antiretroviral therapies increase the therapeutic efficacy
and tolerability, decreasing the risk of developing resistance.
However, the antiretroviral drugs have some disadvantages,
since they have been associated with a redox imbalance,
through the generation of ROS.3 Complementary therapy with
plants with antioxidant properties could help restore the redox
imbalance.
In this work, we evaluated and compared the genomic
instability in HIV patients under antiretroviral therapy with
ATRIPLA and antiretroviral therapy (ATRIPLA) plus
complementary therapy with aqueous or methanolic extract
of R. officinalis.
The average age of the patients with HIV evaluated (40.5
years) was within the age range with the greatest distribution
of the disease (80.5%) reported in Mexico from 1984 to
2018.23
The genomic instability was assessed by the BMCyT
assay. The BMCyT assay has been repeatedly tested as a
reliable biomarker for genotoxicity, cell instability, cell
death, and cancer risk.21,24–26
The group of patients who received the pharmacological
therapy with ATRIPLA showed an increase in the number of
cells with MN, BN, and KR after 4 months of treatment.
This increase may be due to the three active substances
(efavirenz, emtricitabine, and tenofovir) present in ATRI-
PLA (600 mg). Efavirenz is a nucleoside inhibitor of reverse
transcriptase, which acts noncompetitively and reversibly at
the catalytic center of reverse transcriptase, where once lo-
calized it causes the inhibition of gamma polymerase DNA,
generating a decrease in the number of mitochondria and
potentiating oxidative stress.27–29
The liver damage generated by efavirenz is associated
with oxidative stress caused by mitochondrial damage.30–34
Also, the consumption of efavirenz increased the PARP
activity, decreased cell viability, and increased apoptosis
and necrosis.35
Also, HIV has its own mechanism to potentiate the gen-
eration of ROS mediated by viral components such as the
envelope protein Gp120, the Tat gene, Nef, Vpr, and the
reverse transcriptase, each of them acting on different cel-
lular levels but with purpose produce ROS.35–39
It has also been reported that the Vpr gene induces cell
cycle abnormalities with accumulation in the G2/M phase
and increased ploidy, inducing genomic instability.40,41
Our results agree with those previously published by Herd
et al. They reported that HIV individuals receiving anti-
retroviral treatment as well as HIV individuals without
treatment showed an increase in the number of cells with
MN with respect to the follow-up group (consisting appar-
ently healthy seronegative individuals), with the increase in
MN being greater in the patients who took antiretroviral
compared with those who did not.28
Lima et al. determined the number of cells with MN in
oral mucosa in 30 HIV individuals under antiretroviral
therapy and 30 patients without HIV. Patients who received
antiretroviral therapy and low viral load values showed a
higher frequency of multiple MN. The authors concluded
that this may be due to the action of the Vpr gene.42
In contrast, the patients who received the pharmaco-
logical therapy with ATRIPLA and the complementary
therapy with rosemary (methanolic or aqueous extract)
showed a decrease in the number of cells with MN and
NAs. This decrease may be due to the antioxidant effect of
rosemary. Several studies show the antioxidant activity of
R. officinalis.43,44
There are also reports that four diterpenes isolated from
the leaves of R. officinalis (carnosic acid, rosmanol, carno-
sol, and epirosmanol) inhibit the production of superoxide
anion in the xanthine oxidase system, showing a protective
effect against oxidative stress.43
It has been shown that some components of rosemary
(rosmarinic acid, carnosic acid, carnosol, and caffeic acid) can
regulate the activity of peroxisome proliferator-activated re-
ceptors gamma (PPARc).45 PPARc promotes the production
of antioxidant enzymes and in turn modulates the expression
of some genes responsible for inflammation and oxidation.44
In addition, there is evidence to show that Tat gene response
is attenuated by overexpression of PPARa or PPARc.46



























































Furtado et al. reported the capacity of rosmarinic acid
to prevent the breakage or loss of chromosomes induced
chemically with doxorubicin.47
Our results agree with those previously published in pa-
tients with type 2 diabetes mellitus. Patients showed a sig-
nificant decrease in the number of cells with MN, BN, CC,
and Karyorrhectic cells after 30 days after the ingestion of
rosemary aqueous extract from baseline.17
Likewise, the protective effect of methanolic extract of R.
officinalis on DNA damage induced by cyclophosphamide
was demonstrated, as well as the lack of genotoxicity and
cytotoxicity of the extract in mouse peripheral blood by the
micronucleus test.18
It was also shown that R. officinalis decreases damage
to DNA, the anaphase-telophase bridges, and the arsenic-
induced chromosomal aberrations.48
Based on our results, it can be concluded that the com-
plementary therapy with R. officinalis in HIV patients can be
an alternative in the genomic instability decrease generated
by the increase in oxidative stress associated with both the
disease and antiretroviral treatment.
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